Tory Torma, DO
Internal Medicine · Danville, KYNPI 1194255448
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,625 of the $15,199 with a category attached, or 63.3%. AbbVie accounts for 74.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $8,009 and has fallen 52.7% since, to $3,789 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $43.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Lilly USA, LLC$632
- Novo Nordisk$596
- GSK$530
- Amgen$257
- Biohaven Pharmaceutical Holding Company Ltd.$228
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$9,62563%
- Food & beverage$5,54136%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $11,342 |
| Lilly USA, LLC | 45 | $632 |
| Novo Nordisk | 35 | $596 |
| GSK | 30 | $530 |
| Amgen | 14 | $257 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $228 |
| Boston Scientific | 4 | $183 |
| AstraZeneca | 12 | $172 |
| Pfizer | 10 | $142 |
| Novartis | 8 | $127 |
| Xeris Pharmaceuticals, Inc. | 5 | $103 |
| Biohaven Pharmaceuticals, Inc. | 3 | $101 |
| Boehringer Ingelheim | 6 | $101 |
| Almatica Pharma LLC | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $81 |
| Astellas Pharma US Inc | 5 | $80 |
| Axsome Therapeutics, Inc. | 2 | $62 |
| Exact Sciences | 3 | $42 |
| Medtronic | 2 | $36 |
| Corcept Therapeutics | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Bayer | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Verona Pharma, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$5,837
- UBRELVY$4,350
- NURTEC ODT$154
How this compares
$15,199 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 185 | $263,401 |
| TrulicityDulaglutide | 115 | $170,060 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $88,057 |
| FarxigaDapagliflozin Propanediol | 75 | $84,256 |
| JardianceEmpagliflozin | 91 | $83,867 |
| OzempicSemaglutide | 59 | $81,329 |
| Repatha SureclickEvolocumab | 57 | $58,176 |
| UbrelvyUbrogepant | 37 | $57,809 |
| EliquisApixaban | 48 | $55,338 |
| QuliptaAtogepant | 36 | $54,265 |
| JanuviaSitagliptin Phosphate | 34 | $37,381 |
| XareltoRivaroxaban | 29 | $36,857 |
| LinzessLinaclotide | 19 | $15,162 |
| MovantikNaloxegol Oxalate | 24 | $11,055 |
| MyrbetriqMirabegron | 23 | $10,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $632 | $433,461300 claims |
| AbbVieUbrelvy, Qulipta, Linzess, Synthroid | $11,342 | $130,008157 claims |
| Boehringer IngelheimJardiance, Tradjenta | $101 | $92,325102 claims |
| GSKTrelegy Ellipta | $530 | $88,057103 claims |
| AstraZenecaFarxiga | $172 | $84,25675 claims |
| Novo NordiskOzempic | $596 | $81,32959 claims |
| PfizerEliquis | $142 | $55,33848 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $10,41923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Danville
- Justin LandeDanville$60K
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Sanjiv GuptaGrayson$49K
- Kelley McIntyreLouisville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.